| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
"
first quarter 2023 financial results
revenue was $134.3 million for the first quarter of 2023, a 17% increase from $114.5 million for the corresponding prior year period. |
[2023] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
"
first quarter 2023 financial results
revenue was $134.3 million for the first quarter of 2023, a 17% increase from $114.5 million for the corresponding prior year
period. |
[2023] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
"
second quarter 2023 financial results
revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year period.
|
[2023] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
"
second quarter 2023 financial results
revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year
period.
|
[2023] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
• taking actions to reduce spending, preserve cash and strengthen our financial profile, and announcing our goal to become free cash flow positive by
the end of 2023.
|
[2023] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
a hearing on validity is scheduled before the federal patent court in may 2024 and a decision is expected around the end of 2024.
|
[2024] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
a hearing on validity is scheduled before the federal patent court in may 2024 and a decision
is expected around the end of 2024.
|
[2024] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
a hearing on validity is scheduled before the federal patent court in may
2024 and a decision is expected around the end of 2024.
|
[2024] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
a hearing on validity is scheduled before the federal
patent court in may 2024 and a decision is expected around the end of 2024.
|
[2024] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
| 10x Genomics |
|
|
|
|
|
|
TXG |
|
|
|
|
|
|
|
as of december 31, 2018, we had state nols of $93.5 million, which expire beginning in 2032. |
[2032] |
|
0 |
0 |
0 |
0 |
0 |
0 |
1 |
no |
yes |
TXG |
Globenewswire |
https://www.globenewswire.com/news-release/2021/06/10/2245181/0/en/10x-Genomics-Unlocks-Whole-Transcriptome-Analysis-in-FFPE-Tissues-With-New-Visium-Assay-Now-Shipping.html |
|
https://investors.10xgenomics.com/news-events/news-releases |
https://investors.10xgenomics.com/financials/ |
|
not available |
|
United States |
541.715 |
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
334.516 |
Analytical Laboratory Instrument Manufacturing |
0 |
* |
0 |
* |
0 |
* |
|
|
|
15/01/2024 |
